Clinical trials: completed, sponsored by Canadian Cancer Trials Group
Non-Small Cell Lung Cancer
Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC
The purpose of this study is to find out whether it is better to receive a new drug, MEDI4736, or better to receive no further treatment after surgery (and possibly chemotherapy) for lung cancer.
- Trial name
- NCT02273375
- Testing
- MEDI4736
- Where
- 271 sites in United States, Australia and 17 more
- Volunteers
- 1,415 people
- Sponsor
- Canadian Cancer Trials Group
Anxiety Disorder, Cognitive/Functional Effects
Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer
RATIONALE: Participating in a physical activity program designed to increase free time physical activity and receiving written health education materials may influence the chance of cancer recurring as well as impact on physical…
- Conditions
- Anxiety Disorder, Cognitive/Functional Effects, Colorectal Cancer, Depression
- Trial name
- CHALLENGE (NCT00819208)
- Testing
- exercise intervention, counseling intervention, educational intervention
- Where
- 47 sites in United States, Australia and 4 more
- Volunteers
- 889 people
- Sponsor
- Canadian Cancer Trials Group
Prostate Cancer
Feasibility Trial Of Image Guided External Beam Radiotherapy With Or Without High Dose Rate Brachytherapy Boost In Men With Intermediate-Risk Prostate Cancer
This research is being done because investigators involved in this study would like to compare image guided external beam radiation therapy (IGRT) to IGRT plus HDR brachytherapy boost to see which treatment is better and what the…
- Trial name
- NCT01982786
- Testing
- Image guided external beam radiotherapy with or without brachytherapy boost, Brachytherapy
- Where
- 9 sites in Canada
- Volunteers
- 57 people
- Sponsor
- Canadian Cancer Trials Group
Breast Cancer
Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer
The purpose of this study is to determine if the combination of endocrine therapy and Palbociclib at a daily dose of 100 mg will result in a better response to therapy with fewer dose interruptions than the proposed dosing…
- Trial name
- NCT02630693
- Testing
- Palbociclib 100mg, Palbociclib 125mg, Fulvestrant or Tamoxifen or Aromatase Inhibitor
- Where
- 22 sites in Canada
- Volunteers
- 180 people
- Sponsor
- Canadian Cancer Trials Group
Rectal Cancer
NEO: Neoadjuvant Chemotherapy, Excision and Observation for Early Rectal Cancer
The purpose of this study is to find out the effects of chemotherapy followed by less invasive surgery on patients and their early rectal cancer.
- Trial name
- NCT03259035
- Testing
- Folfox Protocol, Capox
- Where
- 11 sites in United States, Canada
- Volunteers
- 58 people
- Sponsor
- Canadian Cancer Trials Group
Prostate Cancer
Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer
The purpose of this study is to find out the effects of giving durvalumab alone or in combination with tremelimumab on this type of cancer.
- Trial name
- NCT02788773
- Testing
- Durvalumab, Tremelimumab
- Where
- 11 sites in Canada
- Volunteers
- 52 people
- Sponsor
- Canadian Cancer Trials Group
Pancreatic Adenocarcinoma
Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma
The standard or usual treatment for this disease consists of two chemotherapy drugs gemcitabine and nab-paclitaxel given together.
- Trial name
- NCT02879318
- Testing
- Gemcitabine, Nab-paclitaxel, Durvalumab
- Where
- 27 sites in Canada
- Volunteers
- 180 people
- Sponsor
- Canadian Cancer Trials Group
Advanced Rare Tumours
Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours
The standard or usual treatment for this disease may be chemotherapy or other types of treatment to slow the spread of the disease and relieve some symptoms of this cancer.
- Trial name
- NCT02879162
- Testing
- Durvalumab, Tremelimumab
- Where
- 13 sites in Canada
- Volunteers
- 140 people
- Sponsor
- Canadian Cancer Trials Group
Cervical Cancer
Radical Versus Simple Hysterectomy and Pelvic Node Dissection With Low-risk Early Stage Cervical Cancer
The reason this study is being done is to see if a simple hysterectomy is as good as a radical hysterectomy in preventing cancer of the cervix from returning, and whether, because less tissue surrounding the uterus is removed…
- Trial name
- SHAPE (NCT01658930)
- Testing
- Radical Hysterectomy + pelvic lymph node dissection, Simple hysterectomy + pelvic lymph node dissection
- Where
- 87 sites in Austria, Belgium and 9 more
- Volunteers
- 700 people
- Sponsor
- Canadian Cancer Trials Group
Mesothelioma
Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma
Pembrolizumab is a new type of drug for mesothelioma (immunotherapy). Laboratory tests show that this drug works by helping improve the body's immune response to help fight cancer.
- Trial name
- NCT02784171
- Testing
- Cisplatin, Pemetrexed, Pembrolizumab
- Where
- 57 sites in Canada, France and 1 more
- Volunteers
- 520 people
- Sponsor
- Canadian Cancer Trials Group
Hepatocellular Carcinoma, Liver Metastases
Study of Palliative Radiotherapy for Symptomatic Hepatocellular Carcinoma and Liver Metastases
The purpose of this study is to see whether one dose of palliative radiation therapy directed to the liver in combination with standard BSC might help to reduce liver pain/discomfort due to cancer when compared to getting…
- Trial name
- NCT02511522
- Testing
- Best Supportive Care, Palliative Radiation Therapy
- Where
- 7 sites in Canada
- Volunteers
- 66 people
- Sponsor
- Canadian Cancer Trials Group
Non-Small Cell Lung Cancer
Selumetinib in Patients Receiving Pemetrexed and Platinum-based Chemotherapy in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous NSCLC
The purpose of this study is to find out what effects a new drug, selumetinib, has on lung cancer when receiving standard chemotherapy with pemetrexed and platinum-based chemotherapy.
- Trial name
- NCT02337530
- Testing
- Selumetinib, Pemetrexed, Cisplatin
- Where
- 12 sites in Canada
- Volunteers
- 62 people
- Sponsor
- Canadian Cancer Trials Group
Spinal Metastases
Study Comparing Stereotactic Body Radiotherapy vs Conventional Palliative Radiotherapy (CRT) for Spinal Metastases
The purpose of this study is to find out if SBRT is better than CRT at controlling pain in the spine 3 months after receiving treatment.
- Trial name
- NCT02512965
- Testing
- 20 Gy in 5 fractions, Conventional SBRT: 24 Gy in 2 fractions
- Where
- 22 sites in Australia, Canada
- Volunteers
- 229 people
- Sponsor
- Canadian Cancer Trials Group
Colorectal Cancer
Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care in Patients With Advanced Colorectal Cancer
The standard or usual treatment for this disease is treatment with drugs and other treatments that may help to make a patient better or may improve their quality of life. This treatment is known as "best supportive care" (BSC).
- Trial name
- NCT02870920
- Testing
- Tremelimumab, Durvalumab, Best Supportive Care
- Where
- 25 sites in Canada
- Volunteers
- 180 people
- Sponsor
- Canadian Cancer Trials Group
Breast Cancer
A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer
This study is looking at whether Metformin, an agent that is commonly used to treat diabetes, can decrease or affect the ability of breast cancer cells to grow and whether Metformin will work with other therapies to keep cancer…
- Trial name
- NCT01101438
- Testing
- metformin hydrochloride
- Where
- 344 sites in United States, Canada and 2 more
- Volunteers
- 3,649 people
- Sponsor
- Canadian Cancer Trials Group
Fallopian Tube Cancer, Metastatic Cancer
Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, carboplatin, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Fallopian Tube Cancer, Metastatic Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Trial name
- NCT00993655
- Testing
- carboplatin, cisplatin, paclitaxel
- Where
- 50 sites in United States, Canada and 2 more
- Volunteers
- 275 people
- Sponsor
- Canadian Cancer Trials Group
Multiple Myeloma
High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma
The purpose of this study is to find out what effects carfilzomib has on relapsed multiple myeloma when administered in combination with cyclophosphamide and dexamethasone.
- Trial name
- NCT02597062
- Testing
- Carfilzomib, Cyclophosphamide, Dexamethasone
- Where
- 9 sites in Canada
- Volunteers
- 76 people
- Sponsor
- Canadian Cancer Trials Group
Breast Cancer
Letrozole in Breast Cancer Who Have Received 5 Years of Aromatase Inhibitor Therapy
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by lowering the amount of estrogen the body makes.
- Trial name
- NCT00754845
- Testing
- letrozole
- Where
- 43 sites in Canada, United Kingdom
- Volunteers
- 1,918 people
- Sponsor
- Canadian Cancer Trials Group
Colorectal Cancer
Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer
The purpose of this study is to find out if giving reolysin in combination with FOLFOX6/ bevacizumab can offer better results than standard therapy with FOLFOX6/ bevacizumab.
- Trial name
- NCT01622543
- Testing
- Folfox plus Bevacizumab and reolysin, Folfox plus Bevacizumab
- Where
- 10 sites in Canada
- Volunteers
- 109 people
- Sponsor
- Canadian Cancer Trials Group
Chronic Lymphocytic Leukemia
Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia
The purpose of this study is to find out what effects a new drug, buparlisib, has on chronic lymphocytic leukemia.
- Trial name
- NCT02340780
- Testing
- Buparlisib
- Where
- 6 sites in Canada
- Volunteers
- 14 people
- Sponsor
- Canadian Cancer Trials Group